✦ LIBER ✦

Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: Results of a pilot study in four patients

✍ Scribed by Anton Hagenbeek; Willemijn Sizoo; Bob Löwenberg

Book ID: 113238235
Publisher: Elsevier Science
Year: 1983
Tongue: English
Weight: 274 KB
Volume: 7
Category: Article
ISSN: 0145-2126
DOI: 10.1016/0145-2126(83)90109-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of “poor risk” acute nonlympho

Treatment of “poor risk” acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

✍ Dr. Edward P. Balaban; John V. Cox; Nancy R. Schneider; Cheryl A. Harth; Barbara 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Results of conventional-dose cytosine ar

Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia

✍ A. Heyll; C. Aul; F. Gogolin; V. Runde; D. Söhngen; G. Meckenstock; H. -H. Wolf; 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 549 KB

Cytosine arabinoside: Results of a coope

Cytosine arabinoside: Results of a cooperative study in acute childhood leukemia

✍ John P. Howard; Vincent Albo; William A. Newton Jr. 📂 Article 📅 1968 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB 👁 3 views

Peripheral neuropathy caused by high-dos

Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia

✍ Takeshi Saito; Osamu Asai; Nobuaki Dobashi; Shingo Yano; Hiroshi Osawa; Yutaka T 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 413 KB

Treatment of acute nonlymphocytic leukem

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

Low-dose Cytosine Arabinoside Therapy in

Low-dose Cytosine Arabinoside Therapy in a Patient with Myelofibrosis during Transformation to Acute Non-lymphocytic Leukemia

✍ JENSEN, MOGENS KROGH ;JOHANSEN, PREBEN ;AHLBOM, GÖRAN 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 166 KB